Utama › Karsinoma Sel Skuamosa Esofagus › Arizona
Kajian klinikal Karsinoma Sel Skuamosa Esofagus di Arizona
6 kajian untuk Karsinoma Sel Skuamosa Esofagus sedang mencari peserta di lokasi di Arizona.
Teks kajian rasmi (Bahasa Inggeris)
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927), Tucson
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05319730A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- City of Hope Cancer Center-Phoenix, Goodyear
- Mayo Clinic Arizona, Phoenix
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277413A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Mayo Clinic Hospital, Phoenix
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT06644781A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- Mayo Foundation for Medical Education and Research - Mayo Cl, Scottsdale
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT06747585First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, Scottsdale
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT07284186A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 111, Tucson
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Nov 2025 · NCT05914116Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.